This document represents the first collaboration between 2 organizations-the American Society for Parenteral and Enteral Nutrition and the Society of Critical Care Medicine-to describe best practices in nutrition therapy in critically ill children. The target of these guidelines is intended to be the pediatric critically ill patient (>1 month and 2-3 days in a PICU admitting medical, surgical, and cardiac patients. In total, 2032 citations were scanned for relevance. The PubMed/MEDLINE search resulted in 960 citations for clinical trials and 925 citations for cohort studies. The EMBASE search for clinical trials culled 1661 citations. In total, the search for clinical trials yielded 1107 citations, whereas the cohort search yielded 925. After careful review, 16 randomized controlled trials and 37 cohort studies appeared to answer 1 of the 8 preidentified question groups for this guideline. We used the GRADE criteria (Grading of Recommendations, Assessment, Development, and Evaluation) to adjust the evidence grade based on assessment of the quality of study design and execution. These guidelines are not intended for neonates or adult patients. The guidelines reiterate the importance of nutrition assessment-particularly, the detection of malnourished patients who are most vulnerable and therefore may benefit from timely intervention. There is a need for renewed focus on accurate estimation of energy needs and attention to optimizing protein intake. Indirect calorimetry, where feasible, and cautious use of estimating equations and increased surveillance for unintended caloric underfeeding and overfeeding are recommended. Optimal protein intake and its correlation with clinical outcomes are areas of great interest. The optimal route and timing of nutrient delivery are areas of intense debate and investigations. Enteral nutrition remains the preferred route for nutrient delivery. Several strategies to optimize enteral nutrition during critical illness have emerged. The role of supplemental parenteral nutrition has been highlighted, and a delayed approach appears to be beneficial. Immunonutrition cannot be currently recommended. Overall, the pediatric critical care population is heterogeneous, and a nuanced approach to individualizing nutrition support with the aim of improving clinical outcomes is necessary.

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)

A.S.P.E.N. and SCCM are both nonprofit organizations composed of multidisciplinary healthcare professionals. The mission of A.S.P.E.N. is to improve patient care by advancing the science and practice of clinical nutrition and metabolism. The mission of SCCM is to secure the highest quality care for all critically ill and injured patients. Guideline Limitations: These A.S.P.E.N.−SCCM Clinical Guidelines are based on general conclusions of health professionals who, in developing such guidelines, have balanced potential benefits to be derived from a particular mode of medical therapy against certain risks inherent with such therapy. However, practice guidelines are not intended as absolute requirements. The use of these practice guidelines does not in any way project or guarantee any specific benefit in outcome or survival. The judgment of the healthcare professional based on individual circumstances of the patient must always take precedence over the recommendations in these guidelines. The guidelines offer basic recommendations that are supported by review and analysis of the current literature, other national and international guidelines, and a blend of expert opinion and clinical practicality. The population of critically ill patients in an intensive care unit (ICU) is not homogeneous. Many of the studies on which the guidelines are based are limited by sample size, patient heterogeneity, variability in disease severity, lack of baseline nutritional status, and insufficient statistical power for analysis. Periodic Guideline Review and Update: This particular report is an update and expansion of guidelines published by A.S.P.E.N. and SCCM in 2009 (1). Governing bodies of both A.S.P.E.N. and SCCM have mandated that these guidelines be updated every three to five years. The database of randomized controlled trials (RCTs) that served as the platform for the analysis of the literature was assembled in a joint “harmonization process” with the Canadian Clinical Guidelines group. Once completed, each group operated separately in their interpretation of the studies and derivation of guideline recommendations (2). The current A.S.P.E.N. and SCCM guidelines included in this paper were derived from data obtained via literature searches by the authors through December 31, 2013. Although the committee was aware of landmark studies published after this date, these data were not included in this manuscript. The process by which the literature was evaluated necessitated a common end date for the search review. Adding a last-minute landmark trial would have introduced bias unless a formalized literature search was re-conducted for all sections of the manuscript. Target Patient Population for Guideline: The target of these guidelines is intended to be the adult (≥ 18 years) critically ill patient expected to require a length of stay (LOS) greater than 2 or 3 days in a medical ICU (MICU) or surgical ICU (SICU). The current guidelines were expanded to include a number of additional subsets of patients who met the above criteria, but were not included in the previous 2009 guidelines. Specific patient populations addressed by these expanded and updated guidelines include organ failure (pulmonary, renal, and liver), acute pancreatitis, surgical subsets (trauma, traumatic brain injury [TBI], open abdomen [OA], and burns), sepsis, postoperative major surgery, chronic critically ill, and critically ill obese. These guidelines are directed toward generalized patient populations but, like any other management strategy in the ICU, nutrition therapy should be tailored to the individual patient. Target Audience: The intended use of these guidelines is for all healthcare providers involved in nutrition therapy of the critically ill, primarily physicians, nurses, dietitians, and pharmacists. Methodology: The authors compiled clinical questions reflecting key management issues in nutrition therapy. A committee of multidisciplinary experts in clinical nutrition composed of physicians, nurses, pharmacists, and dietitians was jointly convened by the two societies.

/pdf/guidelines-for-the-provision-and-assessment-of-nutrition-1t9bnid4wv.pdf

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.).

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

https://www.focusopvoeding.nl/wp-content/uploads/2015/05/JAMDA-PROT-AGE-paperBauer.pdf

Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group

Acute kidney injury (AKI) is a common and serious problem affecting millions and causing death and disability for many. In 2012, Kidney Disease: Improving Global Outcomes completed the first ever, international, multidisciplinary, clinical practice guideline for AKI. The guideline is based on evidence review and appraisal, and covers AKI definition, risk assessment, evaluation, prevention, and treatment. In this review we summarize key aspects of the guideline including definition and staging of AKI, as well as evaluation and nondialytic management. Contrast-induced AKI and management of renal replacement therapy will be addressed in a separate review. Treatment recommendations are based on systematic reviews of relevant trials. Appraisal of the quality of the evidence and the strength of recommendations followed the Grading of Recommendations Assessment, Development and Evaluation approach. Limitations of the evidence are discussed and a detailed rationale for each recommendation is provided.

/pdf/diagnosis-evaluation-and-management-of-acute-kidney-injury-a-5cpql4yj4u.pdf

Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).

Within the last decade, research regarding the human gut microbiome has exploded. While the gastrointestinal tract was once regarded simply as a digestive organ, new technologies have led the science world to wonder about the impact that the gut microbiota may have on human health and disease. The gut microbiome is now becoming known for its role in metabolism, immune defense, and behavior. From in utero variations to those that rapidly occur post partum, our gut microbiome changes with age, environment, stress, diet, and health status as well as medication exposure. This article reviews what is currently known regarding various influences on the gut microbiome and is meant to encourage the reader to further explore the unknown.

Gut Microbiome: What We Do and Don't Know.

https://www.gastrojournal.org/article/S0016-5085(16)00226-2/pdf

Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes

Background/Aim
Impaired gut-liver axis is a potential factor contributing to alcoholic liver disease. Ethanol depletes intestinal integrity and causes gut dysbiosis. Butyrate, a fermentation byproduct of gut microbiota, is altered negatively following chronic ethanol exposure. This study aimed to determine whether prophylactic tributyrin could protect the intestinal barrier and liver in mice during combined chronic-binge ethanol exposure.

Methods
C57BL/6 J mice exposed to 5% v/v ethanol-containing diet for 10 days received a single ethanol gavage (5 g/kg) 9 hrs prior to euthanasia. Control mice were isocalorically pair-fed maltose dextrin for ethanol. Diets were supplemented (5 mM) with tributyrin or glycerol. Intestine and liver disease activity was assessed histologically. Protein and mRNA expression of tight junction proteins (TJ), TLRs and TNFα were assessed. Caco-2 monolayers with/without ethanol exposure and/or sodium butyrate were used to test butyrate's direct effects on intestinal integrity.

Results
Chronic-binge ethanol feeding impaired intestinal TJ protein co-localization staining; however, tributyrin co-treatment mitigated these effects. Ethanol depleted TJ and transepithelial electrical resistance in Caco-2 monolayers, but butyrate co-treatment reduced these effects. Hepatic TLR mRNA expression and TNFα protein expression was induced by ethanol; however, the response was significantly dampened in mice co-treated with tributyrin. Tributyrin altered localization of both neutrophils and single hepatocyte death: leukocytes and apoptotic hepatocytes localized predominantly around the portal tract in ethanol-only treated mice, whereas localization predominated around the central vein in ethanol-tributyrin mice.

Conclusions
Prophylactic tributyrin supplementation mitigated effects of combined chronic-binge ethanol exposure on disruption of intestinal TJ localization and intestinal permeability and liver injury.

/pdf/prophylactic-tributyrin-treatment-mitigates-chronic-binge-4dlfgktwyl.pdf

Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury.

EXCESSIVE ALCOHOL CONSUMPTION is associated with liver injury. Alcoholic liver disease is characterized by fatty liver, hepatitis, fibrosis, and cirrhosis. There is growing appreciation that interorgan crosstalk contributes to ethanol (EtOH)-induced liver injury. Impairment of intestinal barrier function during heavy EtOH exposure is associated with progression of EtOH-induced liver injury in humans and rodents (Rao, 2009). The epithelial barrier is controlled by a variety of specific proteins and intercellular junctional complexes (e.g., occludins, zonula occludens, adherens junctions), together forming a complex called the tight junction (TJ; Rao, 2009). Intact TJs prevent diffusion of macromolecules, such as endotoxin, from the intestine into the lymphatic system and blood stream. Mechanisms by which EtOH impairs the epithelial barrier are not completely understood, but involve complex interactions between reactive EtOH metabolites, changes in intestinal epithelial cell function, as well as shifts in the gut microbiota (Bull-Otterson et al., 2013; Mutlu et al., 2009).

EtOH metabolism, via the alcohol dehydrogenase (ADH) and cytochrome P450 2E1 (CYP2E1) pathways, generates acetaldehyde. Both ADH and CYP2E1 are expressed in liver and intestine, and ADH is also expressed in commensal gut microbiota (Bergheim et al., 2005; Visapaa et al., 2002). While ingested EtOH is primarily absorbed in the proximal small intestine, the distal intestine is exposed to EtOH on the basolateral surface via the blood. EtOH concentration in the colonic lumen is equivalent to that in blood (Halsted et al., 1973). Acetaldehyde increases gut permeability to gut-derived endotoxin by altering intestinal epithelial integrity (Visapaa et al., 2002). Acetaldehyde is further metabolized to acetate by aldehyde dehydrogenase (Geokas et al., 1981). In humans, 70 to 80% of oxidized EtOH appears as free acetate in the hepatic vein (Lundquist et al., 1962). EtOH-derived acetate affects peripheral tissues, for example, acetate has marked effects on central nervous system function (Israel et al., 1994), but it is not clear if acetate also impacts intestinal epithelial integrity.

The gut microbiota is comprised of trillions of commensal bacteria dominated by nearly 800 different species (Hooper et al., 2002). One of the best characterized beneficial functions of gut microbiota is the ability to ferment long-chain polysaccharides that escape human digestion yielding short-chain fatty acids (SCFA). The predominant SCFA produced are acetate, propionate, and butyrate (Canani et al., 2011; Velazquez et al., 1996). Although butyrate is the least abundant SCFA, it serves many biological roles. Butyrate induces epithelial cell proliferation in normal intestinal tissue, but decreases cell proliferation, increases apoptosis, and stimulates cell differentiation in colon cancer cells (Canani et al., 2011). Butyrate stimulates water and electrolyte absorption and inhibits prosecretory action of several cAMP-generating secretagogues, making butyrate beneficial in treating diarrheal disorders (Binder, 2010). Butyrate is the primary fuel source for colonocytes and improves gut barrier function (Canani et al., 2011; Ploger et al., 2012). Butyrate inhibits activation of transcription factor NF-κB, decreasing expression of inflammatory cytokines by colonic epithelial cells (Inan et al., 2000). Absence of intestinal butyrate is associated with apoptosis, inflammation and mucosal atrophy (Hass et al., 1997; Thangaraju et al., 2008, 2009). Higher acetate:butyrate ratios are associated with colonic pathology, including colon polyps and tumors (Weaver et al., 1988).

Multiple concentration-dependent processes regulate intestinal transport of SCFA (Thibault et al., 2010). Mono-carboxylate transporters (MCT), expressed in both apical and basolateral membranes of intestinal epithelial cells, play an important role in absorption of SCFA into the enterocytes from the gut lumen and systemic circulation (Shimoyama et al., 2007). Arterial plasma acetate levels are elevated as much as 20-fold following high-dose EtOH consumption (Lundquist et al., 1962). Therefore, acetate transport from systemic circulation into the gut lumen via MCTs during EtOH consumption is highly likely. Butyrate also interacts with several nutrient sensing G protein–coupled receptors, identified as SCFA receptors (Brown et al., 2003). GPR109A is abundantly expressed in the lumen-facing apical membrane of colonocytes (Thangaraju et al., 2009) and serves as a luminal SCFA sensor (Borthakur et al., 2012). Thus, effects of SCFA are mediated both via activation of these receptors and/or transport into the cell (Brown et al., 2003).

When mice are chronically exposed to high concentrations of EtOH (40 to 60% kcal), gut dysbiosis results (Bull-Otterson et al., 2013; Mutlu et al., 2009; Yan et al., 2011). Acute or binge exposure to EtOH also causes gut dysbiosis, resulting in higher intestinal ratios of Escherichia coli to Lactobacilli, increased plasma endotoxin levels and histological and ultrastructure changes in the intestinal mucosa and epithelia (Zhou et al., 2013). These gut integrity changes are associated with liver injury after acute and chronic EtOH exposure (Bertola et al., 2013; Wang et al., 2012; Zhou et al., 2013). Probiotic supernatant protects against negative effects of acute EtOH exposure on markers of intestinal permeability, endotoxemia, and liver injury (Wang et al., 2012). Similarly, prebiotic and probiotic administration minimizes chronic EtOH-induced changes in gut microbiota (Bull-Otterson et al., 2013; Mutlu et al., 2009) and oral administration of broad-spectrum antibiotics reduces endotoxemia and EtOH-induced liver injury severity in rats (Adachi et al., 1995).

One consequence of gut dysbiosis following EtOH exposure is a skewing of intestinal SCFA concentrations, characterized by higher acetate and lower butyrate concentrations (Xie et al., 2013). Therefore, we hypothesized that the combination of EtOH-induced gut dysbiosis, resulting in lower luminal butyrate concentrations, as well as increased acetate concentrations resulting from EtOH metabolism would negatively alter the acetate:butyrate ratio in the intestinal lumen. Given the important role of butyrate in maintaining gut health and integrity, the purpose of this study was to investigate the effcacy of pharmacologic manipulation of luminal SCFA with the pro-drug tributyrin (glyceryl tributyrate) during EtOH exposure in protecting gut integrity and mitigating EtOH-induced release of liver enzymes, hepatic steatosis, and expression of inflammatory cytokines and chemokines in liver.

Gail A. Cresci

Papers

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

Gut Microbiome: What We Do and Don't Know.

Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes

Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury.

Tributyrin supplementation protects mice from acute ethanol-induced gut injury.